Search results
Mavenclad and cost: Reducing long-term drug costs and more
Medical News Today· 2 days agoMavenclad (cladribine) is a brand-name oral tablet that’s prescribed for certain types of multiple...
Nasdaq finally 'warming up' to Canadian cannabis companies with U.S. exposure. Could American...
Morningstar· 20 hours agoJefferies analyst Owen Bennett on Friday speculated that the Nasdaq could allow U.S.-based cannabis company Curaleaf Holdings (CA:CURA) - which currently trades on the Toronto ...
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
Motley Fool via Yahoo Finance· 7 hours agoBefore you buy Lilly stock though, you should realize the company needs to continue growing earnings...
Saturday Morning News Roundup
San Francisco Chronicle· 10 hours agoThe California Department of Education downgraded its evaluation of the San Francisco Unified School District's budget on concerns that the district won't be able to pay its bills in the next ...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 3 days agoExcluding that, Paxlovid still beat sales forecasts. Notably, revenue from the firm's cardiomyopathy...
Here are the obesity drug hopefuls vying to unseat Ozempic, Zepbound
San Francisco Chronicle· 1 day agoInsatiable demand for weight-loss drugs has made the market so feverish that any positive mention of a potential obesity therapy can send a company’s stock surging - even ...
Novo Nordisk Lifts Guidance as Blockbuster Drug Demand Shows No Signs of Abating — Update
Morningstar· 2 days agoSales in the first quarter were boosted by adjustments to gross-to-net rebates in the U.S.--the discount offered between the list price and the actual net sales price--related ...
The Kentucky Derby is turning 150 years old. It’s survived world wars and controversies of all kinds
Chicago Tribune· 3 hours agoAs a record crowd cheered, American Pharoah rallied from behind and took aim at his remaining two...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 2 days agoModerna stock broke out for the first time in over a year on May 2 after the biotech company notched...
Drug watchdog criticizes Sarepta gene therapy approval, cost - Boston Business Journal
The Business Journals· 22 hours agoThe chief medical officer of a drug pricing watchdog is warning against the FDA granting full...